NEW YORK (GenomeWeb) – AbbVie today announced it is renewing its association with the Structural Genomics Consortium (SGC) for five years with a C$7.5 million (US$5.6 million) cash sponsorship.
The money will be used for open access research to discover new medicines, the firm said in a statement, focusing on chemical tools to explore classes of proteins such as those involved in ion channels, solute carrier channels, and epigenetic regulation.
AbbVie has supported the consortium since 2012.
"We are grateful for AbbVie's funding for our open source laboratory and even more delighted that we and our colleagues in the Ontario institutes, universities, and hospitals can continue to collaborate with AbbVie's world-leading scientists for another five years," SGC CEO Aled Edwards said in a statement.
The SGC offers its research output to the scientific community for free. The consortium is funded by AbbVie, Bayer Pharma, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative, Janssen, Merck, Novartis Pharma, the Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust.
In February, Merck joined the SGC with a C$7.5 million contribution.